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Abstract
Background: The BinaxNOW coronavirus disease 2019 (COVID-19) Ag Card test
(Abbott Diagnostics Scarborough, Inc.) is a lateral flow immunochromatographic point-

Funding and support: This study was financially
supported by Abbott, Inc.

of-care test for the qualitative detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) nucleocapsid protein antigen. It provides results from nasal
swabs in 15 minutes. Our purpose was to determine its sensitivity and specificity for a
COVID-19 diagnosis.
Methods: Eligible patients had symptoms of COVID-19 or suspected exposure. After
consent, 2 nasal swabs were collected; 1 was tested using the Abbott RealTime SARSCoV-2 (ie, the gold standard polymerase chain reaction test) and the second run on the
BinaxNOW point of care platform by emergency department staff.
Results: From July 20 to October 28, 2020, 767 patients were enrolled, of which 735
had evaluable samples. Their mean (SD) age was 46.8 (16.6) years, and 422 (57.4%)
were women. A total of 623 (84.8%) patients had COVID-19 symptoms, most commonly shortness of breath (n = 404; 55.0%), cough (n = 314; 42.7%), and fever (n = 253;
34.4%). Although 460 (62.6%) had symptoms ≤7 days, the mean (SD) time since
symptom onset was 8.1 (14.0) days. Positive tests occurred in 173 (23.5%) and 141
(19.2%) with the gold standard versus BinaxNOW test, respectively. Those with symptoms >2 weeks had a positive test rate roughly half of those with earlier presentations.
In patients with symptoms ≤7 days, the sensitivity, specificity, and negative and positive predictive values for the BinaxNOW test were 84.6%, 98.5%, 94.9%, and 95.2%,
respectively.
Conclusions: The BinaxNOW point-of-care test has good sensitivity and excellent
specificity for the detection of COVID-19. We recommend using the BinasNOW for
patients with symptoms up to 2 weeks.
KEYWORDS

antigen testing, Covid-19, diagnostic devices, emergency department, nasal swab, point of care

1

BACKGROUND

ples revealed a virus with features typical of the beta-coronavirus 2B
lineage of coronavirus,2 and on December 31, 2019, Chinese author-

Although specific dates vary per different reports,1 on December 29,

ities alerted the World Health Organization (WHO). By January 8,

2019, 4 cases of “pneumonia of unknown etiology” were officially

2020, a novel coronavirus was officially announced as the cause of the

reported by local Chinese hospitals. Bronchoalveolar lavage fluid sam-

rapidly spreading illness. The first case reported outside of China was

3 of 8

PEACOCK ET AL .

in Thailand on January 13, 2020. On January 20, 2020, the Centers for
Disease Control and Prevention (CDC) confirmed the first US case.3

The Bottom Line

Ten days later, the WHO declared a global health emergency, and coroIn this multicenter study of 767 emergency department

navirus disease 2019 (COVID-19) was declared a pandemic on March
11, 2020.4 As of August 1, 2021, this pandemic has spread to >200

patients with COVID-19 symptoms or exposure, a point-of-

countries, areas, or territories across the world,5 with an estimated

care antigen test showed good sensitivity (84.6%) and excellent specificity (98.5%) for the detection of COVID-19.

197 million cases and 4.2 million deaths.

1.1

Current COVID-19 testing strategy
and should isolate themselves to help prevent disease spread. It is an

A key aspect in controlling the spread is the need for accurate and

immunochromatographic membrane assay that uses highly sensitive

rapid COVID-19 testing. Molecular testing, as currently employed, is

antibodies to detect the SARS-CoV-2 nucleocapsid protein from nasal

focused on symptomatic individuals and captures only a portion of

swab specimens. SARS-CoV-2-specific antibodies and a control anti-

those who are contagious. Based on CDC estimates,6 40% of infec-

body are immobilized onto a membrane support as 2 distinct lines that,

tions are asymptomatic, and the percentage of transmission occurring

combined with other reagents/pads, construct a test strip. This test

before symptom onset is 50%. Thus, these asymptomatic individuals

strip, and a well to hold the swab specimen, are mounted on oppo-

may unknowingly infect others with whom they come into contact.

site sides of a cardboard, book-shaped hinged test card (Figure 1). It

Laboratory-based reverse transcriptase (RT) polymerase chain reac-

is intended for the qualitative detection of the nucleocapsid protein

tion (PCR) platforms with high sensitivity and specificity are the gold

antigen from SARS-CoV-2 in nasal swabs from individuals suspected

standard for the direct detection of viruses. However, the numbers

of COVID-19 within the first 7 days of symptom onset. This test deliv-

of platforms, technical personnel requirements, reagent and collection

ers results in 15 minutes with no instrumentation using lateral flow

supply limitations, turnaround times, and costs have presented signif-

technology. If accurate, a test with these characteristics would provide

icant challenges. In many cases, including in the emergency depart-

great operational and public health advantages for the ED. Our purpose

ment (ED), it takes several days or more before results are reported

was to determine the sensitivity, specificity, and negative and positive

to the patient. This can increase the spread of contagion as a person

predictive values of this test in a population of suspected patients with

awaits results. Acknowledging the important roles currently served by

COVID-19.

these tests, the fact remains that diagnostic testing, as currently implemented, will not stop this pandemic.

2

1.2

This was a prospective (defined as the data were gathered before

What is needed?

METHODS

the gold standard diagnosis was known), institutional review board–
A paradigm shift is urgently required to address the fundamental need

approved, multicenter study that enrolled a convenience sample of

of identifying individuals who are contagious. A new strategy should

patients from 27 EDs and hospital wards. The specific sites are listed

require a widely deployable diagnostic test with rapid time to results.

in the appendix. Eligible patients were suspected by a healthcare

It must be cost-effective, use a readily accessible sample type (eg, nasal

practitioner of having a COVID-19 infection or exposure. Patients

swab), require no instrumentation, and be rapidly scalable (tens of mil-

were excluded if they had active nose bleeds or acute facial injuries,

lions per month) to enable frequent patient testing. In addition to these

were currently enrolled in a study to evaluate any investigational

criteria, a simple-to-use test that directly detects the severe acute

drug not cleared by the US Food and Drug Administration (FDA), had

respiratory syndrome coronavirus 2 (SARS-CoV-2) antigen would be

already participated in this study, were unable or unwilling to provide

ideal. Although sensitivity is important, the primary goal is to detect

informed consent, or were a member of a vulnerable population

individuals who shed high levels of infectious virus. Evidence suggests

deemed inappropriate for inclusion by the site’s principal investigator.

that most individuals with low levels of virus pose a limited threat of

Vulnerable groups are frequently defined to include children, the

transmission.4–12 A highly specific, rapid, point-of-care ED available

disabled, patients with HIV/AIDS, the elderly, indigenous peoples,

test could provide improved SARS-CoV-2 containment thru more effi-

refugees, and prisoners. There was no age exclusion. Vaccination

cient detection and subsequent isolation of individuals.

status was not recorded as no FDA cleared vaccines were available
during data collection for this trial.

1.3

Testing strategy evaluated by this study
2.1

Performance of the test

The BinaxNOW COVID-19 Ag Card point-of-care test (Abbott Diagnostics Scarborough, Inc.) is an excellent candidate as a first line of

After informed consent and collection of the gold standard nasopha-

defense to identify people who are currently symptomatic, or at risk,

ryngeal swab, research staff collected 2 nasal swabs from each patient.
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CONSORT Flow diagram demonstrating study enrollment

One nasal swab was tested immediately (within 10 minutes) using

The same process was repeated with a second swab; however, the sam-

the BinaxNOW COVID-19 Ag test without elution into viral trans-

ples were obtained in the opposite nare order than the first swab.

port media (VTM). To perform the test, 6 drops of extraction reagent

Eluted VTM nasopharyngeal samples were tested at the core lab-

were added to the top hole of the swab well from a dropper bottle.

oratory, blinded to the BinaxNOW results, on the Abbott RealTime

The patient’s nasal sample swab was then inserted into the test card

SARS-CoV-2 platform (Abbott Diagnostics) provided by the sponsor.

through the bottom hole of the swab well and firmly pushed upward

All reference testing was performed according to product instructions.

until the swab tip was visible through the top hole. Next, the swab was

The PCR cycle threshold (Ct) reported by the Abbott RealTime SARS-

rotated 3 times and the card was closed, bringing the extracted sample

CoV-2 does not include the first 10 thermal cycles that are dark cycles;

into contact with the test strip. Test results were interpreted visually

therefore, the categorical analysis of low viral RNA levels is performed

at 15 minutes based on the determination of the presence or absence

with the Abbott RealTime SARS-CoV-2 test Ct ≥23, which corresponds

of visually detectable pink/purple-colored lines (with no allowance for

to Ct ≥33 for other PCR methods. Each patient’s demographic infor-

a gray zone), and results were recorded using photographs.

mation, self-reported symptom data, reference results, and BinaxNOW

The second nasal swab was placed in VTM and stored at −2◦ C to
−8◦ C until shipped to the core lab. The order of nasal swab collection

COVID-19 Ag test results were recorded in an electronic data capture
(EDC) system.

was randomized according to subject identification (ID) number. For
those with an even-numbered subject ID, the first nasal swab collected
was placed in the BinaxNOW device and the other swab was eluted

2.2

Blinding and external controls

into VTM. For patients with an odd-numbered subject ID, the opposite
sequence occurred.

Test operators were clinical staff blinded to the reference standard

Nasal swab sample collection was performed using gentle rotation,

results, representative of intended users, and did not have professional

with the swab pushed into the nostril until resistance was met at the

training as laboratory technicians. Each day BinaxNOW COVID-19 Ag

level of the turbinate (<1 in. into the nostril). The swab was then

testing was performed, external control testing was done before sub-

rotated several times against the nasal wall, then slowly removed, and

ject testing using positive and negative control swabs. Results were

collection was repeated using the same swab in the opposite nostril.

recorded in a control testing log and entered into the EDC system.
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TA B L E 1

Ease of use questionnaire responses and responses

Question

Strongly
agree

Agree

Neutral

Disagree

Strongly
disagree

No answer

Test procedures instructions were easy to follow

57 (85.1)

9 (13.4)

0

0

0

1 (1.5)

It was easy to process sample (addition of
reagent to card)

60 (89.6)

7 (10.4)

0

0

0

0

It was easy to see and understand results

48 (71.6)

10 (14.9)

2 (3.0)

6 (8.6)

1 (1.5)

0

The control line was always easy to read

56 (83.6)

7 (10.4)

4 (6.0)

0

0

0

The instructions clearly explained how to tell if a
test is invalid

61 (91.0)

5 (7.4)

1 (1.5)

0

0

0

I needed help from someone the first time I ran
the test

17 (25.4)

19 (28.3)

10 (14.9)

9 (13.4)

12 (17.9)

0

Note: Data are provided as n (%).

2.3

Analytic methods

(31.1%), headache (24.8%), myalgia (23.8%), diarrhea (18.4%), lack of
taste/smell (13.6%), rhinorrhea (12.2%), and sore throat (11.6%). Rates

Study enrollment was planned to continue until 120 patients symp-

of symptoms within a temporal cohort were relatively consistent with

tomatic for ≤7 days and positive for COVID-19 by the reference

the passage of time (see Table 2). Although 460 (62.6%) had symptoms

method were identified from an estimated 2200 patients. Planned data

for ≤7 days, the mean (SD) time since symptom onset was 8.1 (14.0)

analysis was for positive and negative agreement, as well as sensitiv-

days. The longest duration of symptoms reported was 182 days, and 56

ity and specificity, between the reference standard and the BinaxNOW

(7.6%) patients had symptoms for ≥14 days.

assay for a diagnosis of SARS-CoV-2 infection. Alternative diagnoses

Of the overall evaluable population, positive tests occurred in

were not recorded nor adjudicated. An interim analysis was con-

173 (23.5%) and 133 (18.1%) patients with the gold standard and

ducted after 30 reference positives were enrolled and used for an FDA

BinaxNOW, respectively. The majority of samples were collected in

Emergency Use Authorization (EUA) submission (which was approved).

those >21 years of age, and the most samples were obtained in

Finally, operation and ease of results interpretation of the BinaxNOW

patients >60 years old. When stratified by symptom duration, those

COVID-19 Ag testing was evaluated by a questionnaire completed by

with symptoms <14 days had the highest rates of positive tests, 25.7%

the staff who performed the test (Table 1).

and 41.9%, for the BinaxNOW and the gold standard test, respectively. Earlier presentations, in those with symptoms <8 days, provided the greatest agreement between the BinaxNOW and the gold

3

RESULTS

standard, 21.5% and 25.4%, respectively. Later presentations, in those
with symptoms >2 weeks, had a positive test rate roughly one quar-

From July 20 to October 28, 2020, 767 patients were enrolled; of

ter of those with an earlier presentation regardless of testing platform.

these, 32 (4.2%) were considered unevaluable and were excluded

When symptoms were reported as >2 weeks, positive tests occurred in

from the analysis. Reasons for exclusions included the BinaxNOW

only 3 (5.4%) and 6 (10.7%) of the BinaxNOW and gold standard tests,

test performance starting >60 minutes after sample collection (n = 8),

respectively.

reference testing conducted >72 hours after sample collection (n = 8),

The overall sensitivity of the BinaxNOW test was 76.9%, but varied

subject eligibility criteria were not met (n = 3), the BinaxNOW test

as a function of symptom duration. It was as high as 84.6% if symptoms

operator was ineligible by training (eg, had prior formal laboratory

were <8 days and declined thereafter (see Table 2). Specificity was con-

training [n = 3] or was not trained in the performance of the BinaxNOW

sistently ≥98%, regardless of the time of presentation. Overall, positive

test [n = 1]), the reference sample was not sent to the reference labora-

and negative predictive values were >93% and were highest within the

tory (n = 4), the reference sample quantity was insufficient to conduct

first week of symptoms.

reference testing (n = 3), the BinaxNOW test result was invalid (n = 1),

Cycle time (Ct) describes the number of PCR cycles required to iden-

or the written informed consent form was invalid (n = 1). There were

tify a virus, with fewer cycles equating to higher virus titers. When

no adverse events related to the testing procedures.

grouped by Ct value, independent of symptom status, the positive

Of the 735 evaluable patients, the mean (SD) age was 47 (16.6) years

agreement of the gold standard and BinaxNOW tests for patients with

(Table 2), of which 57.4% were women and 49.1% were White, 41.4%

Cts <33 was 90.6% (95% confidence interval [CI], 84.2%–95.1%). For

were Black, 1.8% were Asian, and 11.3% were of Hispanic ethnicity.

patients with Cts ≥33, the positive agreement was 37.8% (95% CI,

A total of 625 (84.8%) patients had COVID-19 symptoms, most com-

23.8%–53.5%). When evaluated in patients who were symptomatic,

monly shortness of breath (54.7%), cough (42.7%), and fever (34.4%).

the positive agreement was 90.3% (95% CI, 83.7%–94.9%) and 39.5%

These were followed, in order of decreasing frequency, by fatigue

(95% CI, 25.0%–55.6%), between the gold standard and BinaxNOW
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Demographics and testing results, stratified by symptom duration
Symptoms, n = 623 (84.8%)a
Overall,
N = 735

<8 days,
n = 460

8–14 days,
n = 105

>14 days,
n = 56

No symptoms,
n = 112

Age, y, mean (SD)

47 (16.6)

48 (16.9)

51 (16.0)

51 (13.5)

36 (12.3)

Female sex, n (%)

422 (57.4)

253 (55.0)

58 (55.2%)

31 (55.4)

78 (69.6)

White

362 (49.1)

210 (45.7)

43 (41.0)

21 (37.5)

88 (78.6)

Black

304 (41.4)

217 (47.2)

50 (47.6)

19 (33.9)

16 (14.3)

Asian

13 (1.8)

4 (0.9)

1 (1.0)

1 (1.8)

7 (6.3)

Hispanic

83 (11.3)

40 (8.7)

15 (14.3)

22 (39.3)

6 (5.4)

623 (84.8)

460 (100.0)

105 (100.0)

56 (100.0)

0 (0)

Characteristic

Race/ethnicity, n (%)

Symptoms, n (%)
Any COVID-19 symptom
Shortness of breath

402 (54.7)

286 (62.2)

80 (76.2)

36 (64.3)

0 (0)

Cough

314 (42.7)

221 (48.0)

60 (57.1)

33 (58.9)

0 (0)

Fever

253 (34.4)

193 (42.0)

42 (40.0)

18 (32.1)

0 (0)

Fatigue

229 (31.1)

159 (34.6)

42 (40.0)

28 (50.0)

0 (0)

Headache

182 (24.8)

132 (28.7)

26 (24.8)

24 (42.9)

0 (0)

Myalgias

175 (23.8)

126 (27.4)

32 (30.5)

17 (30.4)

0 (0)

Diarrhea

135 (18.4)

91 (19.8)

28 (26.7)

16 (28.6)

0 (0)

Lack of taste/smell

100 (13.6)

67 (14.6)

21 (20.0)

12 (21.4)

0 (0)

Rhinorrhea

90 (12.2)

68 (14.8)

15 (14.3)

7 (12.5)

0 (0)

Sore throat

85 (11.6)

64 (13.9)

12 (11.4)

9 (16.1)

0 (0)

BinaxNOW

133 (18.1)

99 (21.5)

27 (25.7)

3 (5.4)

4 (3.6)

Gold standard

173 (23.5)

117 (25.4)

44 (41.9)

6 (10.7)

6 (5.4)

84.6 (76.8–90.6)

61.4 (45.5–75.6)

50.0 (11.8–88.2)

66.7 (22.3–95.7)

Positive test

BinaxNOW versus gold standard, % (95% CI)
Sensitivity

76.9 (69.9–82.9)

Specificity

98.6 (97.2–99.4)

98.5 (96.6–99.5)

98.4 (91.2–100.0)

98.0 (89.4–99.9)

99.1 (94.9–100.0)

NPV

93.3 (90.9–95.1)

94.9 (92.1–97.0)

77.9 (67.0–86.6)

94.2 (84.1–98.8)

98.1 (93.4–99.8)

PPV

94.3 (89.1–97.5)

95.2 (89.1–98.4)

96.4 (81.7–99.9)

75.0 (19.4–99.4)

80.0 (28.4–99.5)

Abbreviations: CI, confidence interval; COVID-19, coronavirus disease 2019; NPV negative predictive value; PPV, positive predictive value.
a
Two patients had symptom days missing.

tests, when Ct values were <33 and ≥33, respectively. When strat-

3.1

Limitations

ified between patients with symptom onsets of ≤5, 7, and 10 days,
positive agreement improved, ranging from 94.5% to 96.7% for Ct val-

Our study is not without limitations. Although the use of PCR as a

ues <33 and 27.8% to 48.1% when the Ct was ≥33. Among patients

gold standard provides good biochemical evidence of the presence of

who were asymptomatic, the positive agreement was 100% (95% CI,

SARS-CoV-2, a clinically adjudicated diagnosis may have altered the

39.8%–100%) for Ct values <33 and 0.0% (95% CI, 0.0%–84.2%) for Ct

outcomes of this investigation. Furthermore, the high negative and

values ≥33. The wide CIs in this later cohort are the result of very few

positive predictive values are a function of the disease prevalence

reference patients who were positive and asymptomatic.

when this study was performed, with different populations likely to

Finally, the ease of operations and interpretation of the results ques-

have markedly different outcomes. Notably, although our study did

tionnaire (Table 1) was returned by 67 physicians, nurses, and research

not use laboratory experts, our results can only be applied to test

associates. The majority of answers regarding the ease of use, instruc-

performance by the clinical staff used in this study. Furthermore,

tions, and interpretation of the BinaxNOW platform were all “strongly

although the BinaxNOW test requires user observation of indicator

agree,” except for the question regarding needing help on first-time

colors, collection of interrater reliability data was not obtained.

use, for which only 25% “agreed.”

Whether similar results could be obtained by laypeople using this
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assay in different environments is unclear. In addition, the population

from day 1 to beyond 14 days of symptoms, allows rapid point-of-

studied was a convenience sample of ED patients, and therefore a

care testing, provides a result that can be obtained by a nonlaboratory

sample bias may have occurred. Finally, this study did not evaluate

technician, and has better patient tolerability than a nasopharyngeal

this assay’s performance with newly arising variants; whether it will

test. These features may provide improved identification of individuals

perform equally with different variants is unknown.

infected with SARS-CoV-2 and in those at risk by virtue of exposure to

It should be noted that the enrollment rate per site may be considered low. This is because at the time of the pandemic that this study

known infected individuals. Application of this strategy may represent
another tool to help contain the SARS-CoV-2 pandemic.

was performed, many EDs had simply furloughed their research staff to
protect them from COVID-19, thereby allowing only essential clinical
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